FDA Regulatory Strategy and Consulting

FDA regulatory strategy sets the path your product will follow from early development through marketing application and post-approval life. For drugs and biologics that often means IND planning, NDA or BLA strategy, and clear positions on clinical, nonclinical, and CMC evidence. For devices it can mean 510(k), De Novo, or PMA pathway choices, predicate analysis, and how you will support intended use claims with bench, biocompatibility, software, and clinical data packages that reviewers can follow.

Viltis consultants work inside your program team to turn regulatory risk into decisions you can schedule and fund. We help you map what FDA is likely to ask, where your data package is thin, and which interactions (pre-IND, Type B/C, End-of-Phase, Q-Sub) will reduce uncertainty before you spend on the next study or manufacturing campaign. Strategy here is practical: written positions, milestone gates, and cross-functional alignment so regulatory, clinical, quality, and CMC are telling the same story to leadership and to the Agency.

We do not replace your sponsor obligations or speak for FDA. We help you prepare the rationale, documentation, and meeting materials that make agency dialogue useful. That includes pathway comparisons when more than one option is viable, sequencing advice when U.S. plans must fit with work underway in other regions, and honest assessments when a preferred path looks weak against current guidance or recent review practice in your therapeutic or device area.

Programs stall when regulatory advice stays verbal and unowned. We prefer decision memos, risk registers, and briefing outlines that survive staff turnover and still make sense months later when the next FDA touchpoint arrives. If your internal RA bench is thin, we can embed experienced consultants who keep the strategy current as data, manufacturing, and clinical plans change.

Typical FDA strategy support includes

• Regulatory pathway assessment for drugs, biologics, and medical devices
• IND, NDA, BLA, 510(k), De Novo, and PMA planning inputs
• Briefing document framing and question sets for FDA meetings
• Cross-functional regulatory risk registers and decision memos
• Submission scope definition and gap analysis against guidance
• Ongoing correspondence strategy after major agency feedback

If your team needs seasoned regulatory judgment without building a full in-house RA department overnight, Viltis specialists write clearly, challenge weak assumptions early, and keep development decisions tied to what FDA will actually review.